Compare Stocks

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSD Global System Dynamics	$11.11	$11.16	$9.90 ▼ $11.98	$36.77M	N/A	7,280 shs	2 shs
ONC Oncolytics Biotech	C$1.47 -1.3%	C$1.44	C$1.20 ▼ C$4.49	C$110.87M	1.49	76,504 shs	14,646 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSD Global System Dynamics	0.00%	0.00%	0.00%	-1.24%	+5.61%
ONC Oncolytics Biotech	+1.36%	+4.20%	+7.97%	-9.15%	-14.37%

Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GSD Global System Dynamics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	0.6661 of 5 stars	3.5	0.0	0.0	0.0	1.2	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSD Global System Dynamics	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	3.00	Buy	C$6.00	308.16% Upside

Current Analyst Ratings

Latest IXI, MTPH, ONC, and GSD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/4/2024	ONC Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	C$3.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSD Global System Dynamics	N/A	N/A	N/A	N/A	($1.84) per share	N/A
ONC Oncolytics Biotech	N/A	N/A	C$0.35 per share	4.22	C$0.37 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSD Global System Dynamics	-$790K	N/A	0.00	∞	N/A	N/A	N/A	-2.30%	N/A
ONC Oncolytics Biotech	-C$27.75M	-C$0.41	N/A	∞	N/A	N/A	-102.66%	-55.47%	5/3/2024 (Estimated)

Latest IXI, MTPH, ONC, and GSD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	ONC Oncolytics Biotech	-C$0.15	-C$0.05	+C$0.10	-C$0.05	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSD Global System Dynamics	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSD Global System Dynamics	N/A	0.01	0.01
ONC Oncolytics Biotech	1.54	9.01	8.86

Ownership

Institutional Ownership

Company	Institutional Ownership
GSD Global System Dynamics	24.82%
ONC Oncolytics Biotech	6.98%

Insider Ownership

Company	Insider Ownership
GSD Global System Dynamics	62.81%
ONC Oncolytics Biotech	6.24%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GSD Global System Dynamics	N/A	3.31 million	1.23 million	Not Optionable
ONC Oncolytics Biotech	29	75.42 million	N/A	Not Optionable

IXI, MTPH, ONC, and GSD Headlines

Source	Headline
	Krystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 virus pharmaceutical-technology.com - April 23 at 9:08 AM
	Outrun Therapeutics announces launch with $10m seed funding pharmaceutical-technology.com - April 18 at 7:38 AM
	Biotech expansion for Japanese firm in Holly Springs driven by talent pool, universities carolinapublicpress.org - April 17 at 10:38 AM
	Stocks in play: Oncolytics Biotech® Inc. ca.finance.yahoo.com - April 11 at 3:56 PM
	Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA finance.yahoo.com - April 11 at 8:38 AM
	Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 markets.businessinsider.com - April 10 at 6:01 PM
	Oncolytics Biotech is undervalued, Raymond James says cantechletter.com - April 5 at 3:37 PM
	Oncolytics Biotech (TSE:ONC) Trading Up 10.7% marketbeat.com - April 4 at 10:46 AM
	Closing Bell: Oncolytics Bio down on Friday (ONC) theglobeandmail.com - March 16 at 10:14 AM
	Futures Retreat Sharply msn.com - March 11 at 4:05 PM
	Oncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN finanznachrichten.de - March 6 at 4:39 PM
	Econ Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning finanznachrichten.de - March 6 at 4:39 PM
	A Preview Of Oncolytics Biotech's Earnings benzinga.com - March 6 at 4:39 PM
	Oncolytics Biotech Inc ONC morningstar.com - March 2 at 6:22 PM
	Reiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipeline markets.businessinsider.com - February 15 at 9:24 AM
	Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments finance.yahoo.com - February 15 at 9:24 AM
	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies theglobeandmail.com - February 14 at 2:36 PM
	USA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024 finanznachrichten.de - February 7 at 11:03 AM
	KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses finance.yahoo.com - January 31 at 8:47 PM
	Oncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictions benzinga.com - January 6 at 3:30 PM
	JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON) markets.businessinsider.com - December 14 at 8:26 AM
	Oncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS finanznachrichten.de - December 7 at 8:30 AM
	Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep finance.yahoo.com - November 9 at 7:48 AM
	Oncolytics Biotech's Earnings Outlook benzinga.com - November 3 at 6:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
April 2, 2024 11:25 AM
View Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
Intel's Foundry Woes: Sell Signal or Silver Lining Ahead?
April 5, 2024 8:45 AM
View Intel's Foundry Woes: Sell Signal or Silver Lining Ahead?
Cannabis: One Stock to Play the Movement
April 8, 2024 8:38 AM
View Cannabis: One Stock to Play the Movement
MarketBeat Week in Review – 4/15 - 4/19
April 20, 2024 7:00 AM
View MarketBeat Week in Review – 4/15 - 4/19

All Headlines

Company Descriptions

Global System Dynamics

NASDAQ:GSD

Global System Dynamics, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses its search on the farming and national security sectors, including farming related operations and businesses that support the farming industry. The company was formerly known as Gladstone Acquisition Corporation. Global System Dynamics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Oncolytics Biotech

TSE:ONC

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial